Some research, however, suggests a more drastic dietary change. A 2017 literature review concluded that “whole-foods, plant-based diet—legumes, whole grains, fruits, vegetables, and nuts, with limited or no intake of refined foods and animal products—are highly beneficial for preventing and treating type 2 diabetes.” A 2018 study found that overweight people who switched to a vegan diet for 16 weeks showed improvements in insulin sensitivity compared to a control group.
That is the goal of Imcyse, a French company running a clinical trial with an immunotherapy designed to stop type 1 diabetes. Patients that have been diagnosed within the last 6 months, who still retain some insulin-producing cells, are given a treatment designed to make the immune system destroy the specific immune cells that are attacking insulin-producing cells. Results are expected later this year and will reveal whether the treatment has the potential to become a cure.
Type 2 DM is characterized by insulin resistance, which may be combined with relatively reduced insulin secretion.[11] The defective responsiveness of body tissues to insulin is believed to involve the insulin receptor. However, the specific defects are not known. Diabetes mellitus cases due to a known defect are classified separately. Type 2 DM is the most common type of diabetes mellitus.[2]

“I am extremely pleased to see that technology developed in Tejal Desai’s group is getting to the point that we can explore this for therapeutic purposes,” Matthias Hebrok, PhD, the director of the Diabetes Center at UCSF and a member of Encellin’s scientific advisory board, noted on the UCSF website. “Encapsulation and protection of islet cells remain a critical hurdle that needs to be overcome before cell therapy becomes a reality in type 1 diabetes.”

The gastric bypass that Benari got, for instance, resculpts the digestive system. Surgeons seal off a large part of the stomach using staples, leaving behind a small upper pouch, while rerouting part of the small intestine to the new pouch, bypassing the rest. The net result is that less food can fit in the stomach, and there’s much less time for that food to be turned into calories before it exits the body. The vertical sleeve gastrectomy, the most popular surgery in recent years, only tinkers with the stomach, using staples to turn it into a small banana-shaped organ. (There are less permanent procedures, such as the lap band, but these have fallen out of favor due to their ineffectiveness).
Glucagon is a hormone that causes the release of glucose from the liver (for example, it promotes gluconeogenesis). Glucagon can be lifesaving and every patient with diabetes who has a history of hypoglycemia (particularly those on insulin) should have a glucagon kit. Families and friends of those with diabetes need to be taught how to administer glucagon, since obviously the patients will not be able to do it themselves in an emergency situation. Another lifesaving device that should be mentioned is very simple; a medic-alert bracelet should be worn by all patients with diabetes.
“The field has suffered from a checkered history 20, 30 years ago, when there were operations that were dangerous. But modern metabolic surgery is very safe,” Cummings said. “The risk of dying from a laparoscopic gastric bypass is a little bit less than the risk of dying from having your gallbladder or appendix removed. But we never consider those risky surgeries; they’re totally bread-and-butter procedures.”
Research shows that cognitive behavioral therapy (CBT) combined with medication works best. CBT works by identifying, understanding, and changing thoughts and behaviors, according to the Anxiety and Depression Association of America. As an active participant in your treatment, in CBT you'll do homework and practice exercises over several weeks or months. “This is a new skill that you’re having to fine-tune and develop over time in order to incorporate it into your day-to-day life,” Bereolos says.
Founded in 2007, San Francisco startup NGM Biopharmaceuticals is a pharmaceutical company that has raised $295.4 million, with pharmaceutical giant Merck & Co., as one of its most recent investors. The company has just filed to sell $75 million of its common stock in an IPO. The company’s primary candidate for treating diabetes is NGM313, an engineered antibody that binds to a novel pathway that reduces insulin resistance. After the successful conclusion of a phase I on the drug, NGM plans to license the antibody to Merck.

I was diagnosed as a Type I diabetic in October 1993. I was traveling at the time, and I felt lethargic, I was always thirsty, and I was having trouble concentrating. When I returned home, I went for a checkup, and the doctor confirmed my condition. From that day forward, I’ve been injecting myself with insulin every day. Before I switched to an insulin pump in 2011, I calculated that I had given myself about 30,000 needles. That’s a lot of jabbing.

Diabetes is a disease that occurs when your blood glucose, also called blood sugar, is too high. Blood glucose is your main source of energy and comes from the food you eat. Insulin, a hormone made by the pancreas, helps glucose from food get into your cells to be used for energy. Sometimes your body doesn’t make enough—or any—insulin or doesn’t use insulin well. Glucose then stays in your blood and doesn’t reach your cells.